Dr Matthew Reynolds Addresses Pre-, Postpandemic Implications for Real-world Data and Research
May 20th 2021Matthew Reynolds, PhD, vice president of real-world evidence at IQVIA, discusses findings of a recent paper with the National Pharmaceutical Council on how COVID-19 affected real-world data and research, as well as implications for future studies.
Read More
US Health Plans Addressing Rising Drug Costs With Step Therapy, Value Assessment Frameworks
May 19th 2021As the cost of therapies increases, US health plans are utilizing tools like step therapy, to ensure patients try cheaper alternatives first, and value assessment frameworks, to assist with the decision-making process.
Read More
Mark Trusheim Speaks on ISPOR Payer Summit, Performance-Based Contracting
May 19th 2021Mark Trusheim, MS, BS, strategic director at the NEW Drug Development ParadIGmS program and visiting scientist at Massachusetts Institute of Technology, explains factors involved when considering whether a therapy would be suitable for performance-based contracting.
Read More
Dr Lou Garrison on HTA Utilization, Opportunities for Growth in the Health Care Marketplace
May 18th 2021Lou Garrison, PhD, professor emeritus in the Department of Pharmacy at the University of Washington, explains what is needed to optimize use of health technology assessment (HTA) in the fragmented US health care system.
Read More
Dr J. Jaime Caro Discusses Influence of HEOR, Public Health Amid COVID-19
May 18th 2021J. Jaime Caro, MDCM, FACP, FRCPC, is chief scientist at Evidera, professor in practice at London School of Economics, and adjunct professor of medicine, epidemiology, and biostatistics at McGill University.
Read More
Two posters presented at Virtual ISPOR 2021 analyzed the health care resource utilization and cost of patients with chronic obstructive pulmonary disease (COPD) with pneumonia, as well as the cost savings of treating patients with frequent or severe COPD exacerbations with a fixed-dose triple therapy.
Read More
Dr Vivian Lee on HEOR Integration Amid COVID-19, Implications for Value-Based Care Transition
May 17th 2021Vivian Lee, MD, PhD, MBA, president of health platforms, Verily Life Sciences, discusses examples of health economics and outcomes research (HEOR) use amid the pandemic to optimize patient care, as well as what impact HEOR may have in the transition to a value-based health care system.
Read More
Models Show Switch to Bevacizumab, Rituximab Biosimilars Yields Millions in Savings
May 25th 2020Cost savings are likely to occur should payers switch from originator bevacizumab or rituximab to their respective biosimilars, according to research from 2 studies presented at the Virtual 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting.
Read More
Care Not in Line With Guidelines for HER2-Negative MBC Has Worse Outcomes in Elderly Women
May 23rd 2020More than one-quarter of elderly women with HER2-negative metastatic breast cancer did not receive care in accordance with National Comprehensive Cancer Network (NCCN) treatment guidelines, and that was linked to higher mortality as well as higher Medicare costs.
Read More
What Innovations Can Improve Detection of Predictors, Severity in Parkinson Disease?
May 22nd 2020Presented at Virtual ISPOR 2020, researchers examined the efficacy of a machine learning approach in detecting predictors of Parkinson disease (PD), with an additional study testing the use of a statistical model to predict severity of PD.
Read More
Early Detection Programs May Help Offset Costs of COPD Exacerbations, Studies Find
May 21st 2020Exacerbations of patients with chronic obstructive pulmonary disorder (COPD) can be costly if they are frequent, and early detection programs for COPD may help offset these costs, according to research from 2 studies presented at the 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) virtual conference.
Read More
Studies Outline Asthma's Economic Toll
May 21st 2020Although the total cost of asthma was more than $80 billion in 2013, the expansion of Medicaid in 2014 aided patients with asthma, according to 2 studies presented at the 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) virtual conference.
Read More
Linking Opportunity Costs and Value Assessments for State and Commercial Payers
May 20th 2020When deciding which treatments to cover, states and commercial payers must wrestle with opportunity costs as new therapeutics come to market. A panel at Virtual ISPOR 2020 discussed some of the factors that go into those decisions.
Read More
In 2 abstracts presented at the Virtual ISPOR 2020 meeting, researchers discuss how “OFF” episodes among patients with Parkinson disease may contribute to an increased degree of burden for respective caregivers, with patient preferred on-demand treatments for these episodes also detailed.
Read More
Virtual ISPOR Panel to Examine Next Steps in Value Assessment
May 18th 2020Two of the panelists appearing during the Virtual ISPOR 2020 meeting preview what's needed in improving value assessment: Lou Garrison, PhD, of the University of Washington, and Leah Howard, JD, of the National Psoriasis Foundation.
Read More
Dr Nicholas Robert Outlines How Patients Can Provide More Information on Newly Approved Drugs
August 22nd 2019Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses how patient-reported outcomes collected through real-world data can provide confirmatory information on newly approved drugs.
Read More
Dr Nicholas Robert: Lag Time Between a Drug Approval, Availability in EMRs Can Impact Patient Care
August 10th 2019Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, explains the impact of lag time between a drug's approval and its availability for use in the electronic medical record (EMR).
Read More